NCT04727151: TAC T-cells for the Treatment of HER2-positive Solid Tumors

NCT04727151
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients must have received at least two prior lines of therapy that targeted HER2
Exclusions: 
https://ClinicalTrials.gov/show/NCT04727151

Comments are closed.

Up ↑